Lastly, both S100A9 and KIF2C, as being an integral part of the tumor microenvironment, have been reported as suitable markers for evaluating immunotherapy response (Wagner et al., 2019; Helfen et al., 2021; Liu et al., 2023). This evidence concerns the gene KIF2C and neoplasm.